IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado

Az itteni vizsgálatok

Miről szól a helyszín 5 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák3 vizsgálat
• Prosztatarák2 vizsgálat

Fázis

• 3. fázis5 vizsgálat

Állapot

• Fut, nem toboroz5 vizsgálat

Fő szponzor

• Janssen Research & Development, LLC5 vizsgálat

Futó vizsgálatok

• Fut, nem toboroz

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· 3. fázis· Janssen Research & Development, LLC· Forrás